Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.

Kenji SekiguchiNobuo KoharaMasayuki BabaTetsuo KomoriYutaka NaitoTomihiro ImaiJo SatohYasuyuki YamaguchiTatsuto Hamataninull null

Published in: Journal of diabetes investigation (2018)

Ranirestat (40 mg/day) was well tolerated and improved nerve conduction velocity. Regarding symptoms and signs, no detectable benefits over the placebo were observed in the ranirestat group during the 52 weeks of treatment.

Keyphrases

double blind
placebo controlled
clinical trial
blood flow
peripheral nerve
phase iii
type diabetes
phase ii